Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Infectious Diseases

Set Alert for Infectious Diseases

VBI Poised To Take On GSK, Dynavax As Hep B Vaccination Market Takes Off

VBI Vaccines obtained FDA approval of its three-antigen hepatitis B vaccine PreHevbrio and will take on GSK’s Engerix-B and Dynavax’s Heplisav-B as CDC recommends universal HBV immunization.

Approvals Vaccines

GSK Looks To Long-Acting Therapy To Restore Lead In HIV

GSK looks to Cabenuva to get ahead in the long-acting HIV therapy and PrEP market, but Gilead will not relinquish its lead easily.

Companies Research & Development

NRx’s COVID-19 Vaccine Candidate BriLife Impresses In Phase II

NRx’s BriLife has demonstrated strong potential in early data from a mid-stage COVID-19 trial, spurring the company on to begin a Phase IIb/III study as soon as possible.

Coronavirus COVID-19 Infectious Diseases

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: the prospects and plans for J&J’s pharma and oncology business; China looks more inward under new policies; an important US approval for Takeda; and Moderna’s co-founder shares tips on innovation.

Business Strategies Commercial

Pfizer/BioNTech’s Comirnaty Supply Agreements Unaffected Despite EU Green Light For Under-12s

Pfizer and BioNTech’s Comirnaty supply under existing agreements will continue as planned despite anticipated expansion into a new child sub-population in Europe.

Vaccines Regulation

Gilead Trial Pause Adds To Merck & Co’s HIV Concerns

The partners are halting recruitment out of “an abundance of caution,” but Gilead could decide to exit the alliance if islatravir cannot shake off safety concerns.

Infectious Diseases Companies

Nykode Enters New Phase With Regeneron Vaccine Pact

Regeneron is investing heavily to advance five vaccine programs with Nykode Therapeutics, the Norwegian company formerly known as Vaccibody.

Vaccines Deals

Safety Concerns Halt Merck & Co’s Once-Weekly HIV Combination

Merck & Co. is looking to compete in the burgeoning long-acting HIV market, but a safety halt to a Phase II trial could disrupt those plans.

Clinical Trials Companies

Big Pharma Must Diversify To Tackle Antimicrobial Resistance

Big pharma must bet on biotech if the industry is to tackle the looming issue of superbugs, argues the Access To Medicine Foundation.

Infectious Diseases Companies

China First Domestic COVID-19 Antibody Therapy Moves Towards Green Light

Brii’s antibody combo therapy nears approval in China, based on data from a late-stage study conducted outside the country.

China Coronavirus COVID-19

Novartis and Molecular Partners’ Ensovibep Flunks In ACTIV-3 In Hospitalized COVID-19 Patients

Ensovibep failed to meet thresholds for continued enrollment in the large NIH Phase III trial, forcing Novartis and Molecular to home in on the early COVID-19 setting instead.

Clinical Trials Infectious Diseases

Roche Exit Strengthens Pfizer And Merck & Co In Covid Pill Market

Roche has bowed out of the race to develop an oral COVID-19 therapy, leaving a lucrative but likely short-lived market for its rivals.

Companies Coronavirus COVID-19
See All
UsernamePublicRestriction

Register